Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 600.

https://doi.org/10.1182/blood-2024-198075

Published: 2024

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, MD, Maria Teresa Gómez Casares, MDPhD, Jesper Stentoft, MD PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Valentin García-Gutiérrez, MD, Norbert Gattermann, MD, Wieslaw Wiktor-Jedrzejczak, MD, Philipp D. Le Coutre, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MB, MD FRCPI, FRCPath, Jerald P. Radich, David M. Ross, MBBS, PhD FRACP, FRCPA, Hans D. Menssen, MD PhD, Weiping Deng, Patricia Brandt, Ari Gnanasakthy, MBA, MSc, Veronique Bedoucha, Giuseppe Saglio, MD

Blood (2016) 128 (22): 3066.

https://doi.org/10.1182/blood.V128.22.3066.3066

Published: 2016

Journal Articles

Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study

Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, MD, Jeffrey Szer, Uwe Platzbecker, MD, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, MD, Nancy Carpenter, Bhakti Mehta, Janet Franklin, Aristoteles Giagounidis

Blood (2016) 128 (22): 2000.

https://doi.org/10.1182/blood.V128.22.2000.2000

Published: 2016

Journal Articles

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3 -ITD + normal karyotype AML patients

Blood (2016) 127 (3): 360–362.

https://doi.org/10.1182/blood-2015-08-662130

Published: 2016

Includes: Supplemental data

Journal Articles

Hemophagocytic Lymphohistiocytosis (HLH) in 44 Adults: Results from the Retrospective Polish Registry

Blood (2015) 126 (23): 4613.

https://doi.org/10.1182/blood.V126.23.4613.4613

Published: 2015

Journal Articles

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop Kantarjian, MD, Ghulam J. Mufti, MD PhD, Pierre Fenaux, MD PhD, Mikkael A. Sekeres, MD MS, Jeffrey Szer, MB BS FRACP, Uwe Platzbecker, MD, Andrea Kuendgen, MD, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, MD PhD, Janet Franklin, MD MPH, Aristoteles Giagounidis, MD

Blood (2015) 126 (23): 2863.

https://doi.org/10.1182/blood.V126.23.2863.2863

Published: 2015

Journal Articles

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Blood (2015) 126 (6): 739–745.

https://doi.org/10.1182/blood-2015-03-635326

Published: 2015

Includes: Supplemental data

Journal Articles

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Blood (2014) 124 (21): 4742.

https://doi.org/10.1182/blood.V124.21.4742.4742

Published: 2014

Journal Articles

Treatment with Romiplostim, a Thrombopoietin-Receptor Agonist, in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Updated Follow-up Results for Acute Myeloid Leukemia (AML) and Survival from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop M. Kantarjian, Ghulam Mufti, Pierre Fenaux, Mikkael Sekeres, Jeffrey Szer, Uwe Platzbecker, Andrea Kuendgen, MD, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, Amelia Orejudos, Angela Lopez, Aristoteles Giagounidis

Blood (2014) 124 (21): 3276.

https://doi.org/10.1182/blood.V124.21.3276.3276

Published: 2014

Journal Articles

Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study

Blood (2014) 124 (21): 4453.

https://doi.org/10.1182/blood.V124.21.4453.4453

Published: 2014

Journal Articles

Conditioning Intensity Does Not Influence the Outcome of Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome. a Joint Study By the Polish Adult Leukemia Group and the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation

Blood (2014) 124 (21): 2564.

https://doi.org/10.1182/blood.V124.21.2564.2564

Published: 2014

Journal Articles

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Blood (2014) 124 (21): 2120.

https://doi.org/10.1182/blood.V124.21.2120.2120

Published: 2014

Journal Articles

Treatment With Romiplostim, a Thrombopoietin-Receptor Agonist, In Thrombocytopenic Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndrome: Updated Follow-Up Results For Acute Myeloid Leukemia and Survival From a Randomized, Double-Blind, Placebo-Controlled Study

Hagop M. Kantarjian, MD, Ghulam J. Mufti, MD, PhD, Pierre Fenaux, MD, PhD, Mikkael A. Sekeres, MD, MS, Jeffrey Szer, MBBS, Uwe Platzbecker, MD, PhD, Andrea Kuendgen, MD, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, Anne Meibohm, PhD, Angela Lopez, Aristoteles Giagounidis, MD

Blood (2013) 122 (21): 1553.

https://doi.org/10.1182/blood.V122.21.1553.1553

Published: 2013

Journal Articles

EBMT Prospective Non-Interventional Study On Allogeneic Hematopoietic Stem Cell Transplantation In T-Prolymphocytic Leukemia (T-PLL). Preliminary Analysis Of 43 Patients

Wieslaw Wiktor Jedrzejczak, M.D., Ph.D., Simona Iacobelli, Ph. D., Jennifer D.C. Hoek, Ph.D., Joanna E Drozd-Sokolowska, M.D., Ph.D., Michael Potter, MD, PhD, Gerald Wulf, MD, Patrice Chevallier, MD, PhD, Per T. Ljungman, MD, PhD, Yener Koc, MD, Johannes Schetelig, MD, M. Sc, Theo de Witte, MD, Nicolaus Kroeger, MD, Peter Dreger, MD

Blood (2013) 122 (21): 3336.

https://doi.org/10.1182/blood.V122.21.3336.3336

Published: 2013

Journal Articles

FLT3-ITD and MLL -PTD Mutations Influence the Expression of MDR1, MRP1 and BCRP mRNA in Adult Acute Myeloid Leukemia

Barbara Nasilowska-Adamska, Iwona Solarska, Monika Paluszewska, Wieslaw Wiktor Jedrzejczak, Piotr Rzepecki, Bozena Marianska, Krzysztof Warzocha

Blood (2012) 120 (21): 1334.

https://doi.org/10.1182/blood.V120.21.1334.1334

Published: 2012

Journal Articles

Bendamustine in Monotherapy and in Combination Regimens in the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma – a Retrospective Analysis

Iwona Hus, Dariusz Jawniak, Magdalena Gorska-Kosicka, Aleksandra Butrym, Justyna Dzietczenia, Tomasz Wrobel, Grzegorz Mazur, MD, PhD, Ewa Lech-Maranda, Krzysztof Warzocha, MD, PhD, Anna Waszczuk-Gajda, Wieslaw Wiktor-Jedrzejczak, MD, PhD, Malgorzata Krawczyk-Kulis, Slawomira Kyrcz-Krzemien, MD PhD Prof, Lidia Poplawska, Jan Walewski, Anna Dmoszynska

Blood (2012) 120 (21): 4602.

https://doi.org/10.1182/blood.V120.21.4602.4602

Published: 2012

Journal Articles

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop M. Kantarjian, MD, Ghulam J. Mufti, MD, Pierre Fenaux, MD, PhD, Mikkael A. Sekeres, MD, MS, Jeffrey Szer, MBBS, Uwe Platzbecker, MD, Andrea Kuendgen, Gianluca Gaidano, MD, PhD, Wieslaw Wiktor-Jedrzejczak, MD, PhD, John M. Bennett, MD, Anne Meibohm, PhD, Allen S. Yang, MD, PhD, Aristoteles Giagounidis, MD

Blood (2012) 120 (21): 421.

https://doi.org/10.1182/blood.V120.21.421.421

Published: 2012

Journal Articles

Daunorubicine, Cytarabine and Cladribine (DAC) Vs Daunorubicine and Cytarabine (DA) Induction Treatment in Elderly Acute Myeloid Leukemia (AML) Patients – Results of the Prospective, Multicenter, Randomized Trial of the Polish Adult Leukemia Group (PALG)

Blood (2012) 120 (21): 3602.

https://doi.org/10.1182/blood.V120.21.3602.3602

Published: 2012

Journal Articles

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

Blood (2012) 120 (18): 3670–3676.

https://doi.org/10.1182/blood-2012-06-438804

Published: 2012

Journal Articles

Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

Blood (2012) 119 (18): 4253–4263.

https://doi.org/10.1182/blood-2011-10-385658

Published: 2012

Includes: Supplemental data

NARROW

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3 -ITD + normal karyotype AML patients

Hemophagocytic Lymphohistiocytosis (HLH) in 44 Adults: Results from the Retrospective Polish Registry

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study

Conditioning Intensity Does Not Influence the Outcome of Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome. a Joint Study By the Polish Adult Leukemia Group and the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Treatment With Romiplostim, a Thrombopoietin-Receptor Agonist, In Thrombocytopenic Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndrome: Updated Follow-Up Results For Acute Myeloid Leukemia and Survival From a Randomized, Double-Blind, Placebo-Controlled Study

EBMT Prospective Non-Interventional Study On Allogeneic Hematopoietic Stem Cell Transplantation In T-Prolymphocytic Leukemia (T-PLL). Preliminary Analysis Of 43 Patients

FLT3-ITD and MLL -PTD Mutations Influence the Expression of MDR1, MRP1 and BCRP mRNA in Adult Acute Myeloid Leukemia

Bendamustine in Monotherapy and in Combination Regimens in the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma – a Retrospective Analysis

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Daunorubicine, Cytarabine and Cladribine (DAC) Vs Daunorubicine and Cytarabine (DA) Induction Treatment in Elderly Acute Myeloid Leukemia (AML) Patients – Results of the Prospective, Multicenter, Randomized Trial of the Polish Adult Leukemia Group (PALG)

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only